RxDoctor Payments Data

Derek Taylor, MD

Gastroenterology · Portland, ORNPI 1487766911

Payments from drug & device makers

$428in general payments, 2019–2025

Across 13 payments — averaging $32.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$190
  • AbbVie$142
  • Johnson & Johnson$49
  • Olympus America Inc.$28
  • Pfizer$19

What the payments were for

  • Food & beverage$428100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific3$190
AbbVie(2 entities)6$142
Johnson & Johnson2$49
Olympus America Inc.1$28
Pfizer1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$428 in reported general payments places this provider in the 45th percentile of 220 gastroenterology providers in Oregon.

See all gastroenterology providers in Oregon

Medicare billing

Part B allowed, 2024
$155,223
Medicare patients
237
Services billed
4,553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$350,543
ZenpepLipase/Protease/Amylase13$53,659
CreonLipase/Protease/Amylase17$47,553
Mesalamine15$13,069
Mesalamine ErMesalamine38$9,762
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates81$5,269
Ondansetron OdtOndansetron14$4,813
Sucralfate29$3,668
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg154$3,630
Octreotide Acetate12$3,577
Ursodiol16$3,324
Omeprazole134$2,297
Azathioprine21$1,649
Budesonide DrBudesonide14$1,207
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine15$1,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$49$350,54313 claims
AbbVieCreon$142$47,55317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 220 gastroenterology providers in Oregon.

Other gastroenterology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →